163 related articles for article (PubMed ID: 22250187)
1. Prediction of sentinel lymph node positivity by growth rate of cutaneous melanoma.
Tejera-Vaquerizo A; Nagore E; Herrera-Acosta E; Martorell-Calatayud A; Martín-Cuevas P; Traves V; Herrera-Ceballos E
Arch Dermatol; 2012 May; 148(5):577-84. PubMed ID: 22250187
[TBL] [Abstract][Full Text] [Related]
2. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
3. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
[TBL] [Abstract][Full Text] [Related]
4. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.
Azimi F; Scolyer RA; Rumcheva P; Moncrieff M; Murali R; McCarthy SW; Saw RP; Thompson JF
J Clin Oncol; 2012 Jul; 30(21):2678-83. PubMed ID: 22711850
[TBL] [Abstract][Full Text] [Related]
7. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
[TBL] [Abstract][Full Text] [Related]
8. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
[TBL] [Abstract][Full Text] [Related]
9. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004.
Berk DR; Johnson DL; Uzieblo A; Kiernan M; Swetter SM
Arch Dermatol; 2005 Aug; 141(8):1016-22. PubMed ID: 16103331
[TBL] [Abstract][Full Text] [Related]
10. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.
Debarbieux S; Duru G; Dalle S; Béatrix O; Balme B; Thomas L
Br J Dermatol; 2007 Jul; 157(1):58-67. PubMed ID: 17501957
[TBL] [Abstract][Full Text] [Related]
11. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
[TBL] [Abstract][Full Text] [Related]
12. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
[TBL] [Abstract][Full Text] [Related]
13. A retrospective, multicenter analysis of the predictive value of mitotic rate for sentinel lymph node (SLN) positivity in thin melanomas.
Wat H; Senthilselvan A; Salopek TG
J Am Acad Dermatol; 2016 Jan; 74(1):94-101. PubMed ID: 26542815
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker.
Callender GG; Egger ME; Burton AL; Scoggins CR; Ross MI; Stromberg AJ; Hagendoorn L; Martin RC; McMasters KM
Am J Surg; 2011 Dec; 202(6):659-64; discussion 664-5. PubMed ID: 22137134
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma.
Kunte C; Geimer T; Baumert J; Konz B; Volkenandt M; Flaig M; Ruzicka T; Berking C; Schmid-Wendtner MH
Melanoma Res; 2010 Aug; 20(4):330-7. PubMed ID: 20526218
[TBL] [Abstract][Full Text] [Related]
16. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis.
Roka F; Kittler H; Cauzig P; Hoeller C; Hinterhuber G; Wolff K; Pehamberger H; Diem E
Br J Cancer; 2005 Feb; 92(4):662-7. PubMed ID: 15700039
[TBL] [Abstract][Full Text] [Related]
17. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.
Paek SC; Griffith KA; Johnson TM; Sondak VK; Wong SL; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
Cancer; 2007 Jan; 109(1):100-8. PubMed ID: 17146784
[TBL] [Abstract][Full Text] [Related]
18. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy.
Morris KT; Busam KJ; Bero S; Patel A; Brady MS
Ann Surg Oncol; 2008 Jan; 15(1):316-22. PubMed ID: 18004626
[TBL] [Abstract][Full Text] [Related]
19. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma.
Sabel MS; Griffith K; Sondak VK; Lowe L; Schwartz JL; Cimmino VM; Chang AE; Rees RS; Bradford CR; Johnson TM
J Am Coll Surg; 2005 Jul; 201(1):37-47. PubMed ID: 15978442
[TBL] [Abstract][Full Text] [Related]
20. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI).
Testori A; De Salvo GL; Montesco MC; Trifirò G; Mocellin S; Landi G; Macripò G; Carcoforo P; Ricotti G; Giudice G; Picciotto F; Donner D; Di Filippo F; Soteldo J; Casara D; Schiavon M; Vecchiato A; Pasquali S; Baldini F; Mazzarol G; Rossi CR;
Ann Surg Oncol; 2009 Jul; 16(7):2018-27. PubMed ID: 19132446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
